Last reviewed · How we verify
the dexmedetomidine group
Dexmedetomidine, marketed by Yonsei University, holds a position in the anesthetic and sedative market with its key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence, supported by robust clinical trial results. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | the dexmedetomidine group |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Effect of CYP2D6 on Perioperative Analgesia of Oxycodone in Elderly Patients
- Comparison Between Dexamethasone and Dexmedetomidine in Spinal Anesthesia for Cases With Fracture Pelvis Fixation (EARLY_PHASE1)
- Cardiac Index and General Anesthesia Without Opioid. (PHASE2, PHASE3)
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- the dexmedetomidine group CI brief — competitive landscape report
- the dexmedetomidine group updates RSS · CI watch RSS
- Yonsei University portfolio CI